Title of article
Intralesional Injection of the Measles–Mumps– Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial
Author/Authors
Rezai, Mohammad Sadegh Pediatric Infectious Diseases Superspecialist - Infectious Diseases Research Center with focus on Nosocomial Infections - Mazandaran University of Medical Sciences - Sari, Iran , Ghasempouri, Hiva General physician - Mazandaran University of Medical Sciences - Sari, Iran , Marzidareh, Ozra Asqary General physician - Mazandaran University of Medical Sciences - Sari, Iran , Rahmatpour Rokni, Ghasem General physician - Mazandaran University of Medical Sciences - Sari, Iran , Yazdani Cherati, Jamshid Department of Biostatistics - Health Sciences Research Center - Mazandaran University of Medical Sciences - Sari, Iran
Pages
8
From page
10
To page
17
Abstract
Common resistant-to-therapy warts pose
a challenge to both clinicians and patients. Among many
destructive and immunotherapeutic options, no single, fully
effective treatment has been suggested yet. Many investigations,
including those using intralesional antigen administrations, have
demonstrated that cellular immunity plays a major role in the
clearance of human papilloma virus (HPV) infection. The aim of
the present study was to evaluate the effects of the intralesional
injection of the measles–mumps–rubella (MMR) vaccine into
resistant-to- treatment palmoplantar warts and its complications.
Methods: In this single-blind, randomized, controlled clinical
trial, 60 cases with resistant-to-therapy palmoplantar warts
referring to the Dermatology Clinic of Bou-Ali Sina Hospital
of Sari between June 2015 and 2016 were randomly assigned
to 2 equal groups: the MMR Group received intralesional
MMR and the Placebo Group was given saline injection. The
injections were administered at 2-week intervals until complete
clearance was achieved or for a maximum of 5 injections
(<5 injections at 2-week intervals). The study protocol was
registered in the Iranian Registry of Randomised Clinical Trials
(ID: IRCT2016101027636N3), and the statistical analyses were
performed using SPSS, version 17.0. The χ2 test and the F-test
were used as appropriate, and a P value less than 0.05 was
considered statistically significant.
Results: Complete clearance was observed in 65.2% (14⁄23) of
the patients presenting with resistant-to-therapy palmoplantar
warts in the MMR Group and 23.85% (5/21) in the Placebo
Group (P=0.021). Recurrence was not observed in any of the
completely cured patients at 6 months’ follow-up.
Conclusion: Intralesional immunotherapy with the MMR
vaccine may result in a desirable therapeutic response and can be
used as an effective and safe treatment option for palmoplantar
warts, particularly persistent ones.
Keywords
Warts , Measles–mumps– rubella vaccine , Injections Intralesional
Journal title
Astroparticle Physics
Serial Year
2019
Record number
2485231
Link To Document